TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05150834

Intervention type: OTHER
Intervention: This is observational study
Description: We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.

Intervention type: OTHER
Intervention: This is observational study
Description: We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
Study: NCT05270642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Thermal guided by Plan for Microwave Thermal Field system
Description: When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
Study: NCT05045352

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: echogenic needles for intravenous access
Description: echogenic needles for intravenous access (subclavian vein) ultrasound guided procedure
Study: NCT05645770

Intervention type: COMBINATION_PRODUCT
Intervention: ECG, computerized task
Description: ECG for cardiac waves computerized task for prospective memory

Intervention type: COMBINATION_PRODUCT
Intervention: ECG, computerized task
Description: ECG for cardiac waves computerized task for prospective memory
Study: NCT05483582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study: NCT05042934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration
Description: Undergo fine-needle aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given IV
Study: NCT06225115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet
Study: NCT05626426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Description: Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
Study: NCT05684471

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Suprainguinal Fascia iliaca Block
Description: Patients in this group will be administered SFIB with 50 mL of local anesthetic solution (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Anterior Quadratus Lumborum Block
Description: Patients in this group will be administered anterior QLB with 40 mL of local anesthetic (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
Study: NCT06163599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Telenovela Intervention
Description: The intervention constitutes nine videos depicting the main character, Esperanza, who is struggling with anxiety and depression, undergoing therapy involving the a trandiagnostic treatment, and completing worksheets relating to the weekly therapy sessions.
Study: NCT06127368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-5001A
Description: Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-5001D
Description: Depending on the cohort, volume will be varied to administer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cohort
Description: Single dose of Aricept tablet.
Study: NCT06273202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Massage
Description: Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
Study: NCT06213870

Intervention type: DIAGNOSTIC_TEST
Intervention: Surgical criteria
Description: In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.~In the perfusion group, patients who meet the criteria of DEFUSE3 will receive EVT surgery, otherwise receive medication.

Intervention type: DIAGNOSTIC_TEST
Intervention: Surgical criteria
Description: In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.~In the perfusion group, patients who meet the criteria of DEFUSE3 will receive EVT surgery, otherwise receive medication.
Study: NCT05726760

Intervention type: BEHAVIORAL
Intervention: Seeking informed consent for participation in the study.
Description: The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.

Intervention type: BEHAVIORAL
Intervention: Seeking informed consent for participation in the study.
Description: The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.

Intervention type: DEVICE
Intervention: Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.
Description: The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
Study: NCT06409299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 40 MG/ML
Description: Maintenance Antibiotic treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05670834

Intervention type: GENETIC
Intervention: genotyping assay by real-time PCR
Description: genotyping assay of MMP-2 gene with the real-time polymerase chain reaction

Intervention type: GENETIC
Intervention: genotyping assay by real-time PCR
Description: genotyping assay of MMP-2 gene with the real-time polymerase chain reaction

Intervention type: GENETIC
Intervention: genotyping assay by real-time PCR
Description: genotyping assay of MMP-2 gene with the real-time polymerase chain reaction

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: . IL-6 level in serum will be analyzed by ELISA assay kit.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: . IL-6 level in serum will be analyzed by ELISA assay kit.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: . IL-6 level in serum will be analyzed by ELISA assay kit.
Study: NCT05897632

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Outpatient Evaluation
Description: Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hospitalization Evaluation
Description: Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
Study: NCT05726760

Intervention type: DEVICE
Intervention: Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.
Description: The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
Study: NCT06162897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Case Management
Description: Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals.
Study: NCT06522724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Description: Patients in a study group will participate in daily education program using an original brochure containing information about self-management during the treatment process, the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
Study: NCT05746754

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CSI
Description: 30 Gy in 10 fractions to CNS
Study: NCT06553053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harmonizing Shaoyang, nourishing spleen and kidney with warmth Acupuncture Group
Description: Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nourishing spleen and kidney with warmth Acupuncture Group
Description: Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
Study: NCT06332404

Intervention type: DEVICE
Intervention: Hypoglossal nerve stimulation Inspire system (Inspire Medical Systems Inc., USA)
Description: Hypoglossal nerve stimulation therapy
Study: NCT05393804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ide-cel (bb2121)
Description: Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ide-cel (bb2121)
Description: Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.
Study: NCT06290882

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Heller Myotomy
Description: Use five trocar technique with patient in the French position. Establish 12-15 mm Hg pneumoperitoneum. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 7 cm above gastroesophageal junction and 2 cm inferiorly over stomach. Measure myotomy length. Perform anterior fundoplication without mobilizeng fundus of the stomach by dividing short gastric vessels if not necessary. Suture fundus to both cut edges of myotomy, using non-resorbable material.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy
Description: After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
Study: NCT05743751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion
Description: XVIVO (perfusion company, Gothenburg, Sweden), functions to be included in perfusion equipment, cardiopulmonary bypass machine and neonatal cardiopulmonary bypass machine, including polyethylene pipeline, heating equipment (perfusion temperature 37 ℃), venous pool (venous pressure is 0 mmHg, adjust the height of perfusion pool), centrifugal pump (arterial pressure is set at initial 75 mmHg, maintain 65 mmHg). The perfusion solution contains 215ml of dextran/albumin solution and 400ml of hematocrit, 2ml of 10% calcium gluconate, 1300u/L heparin and 400mg of cefazolin sodium. The oxygen/carbon dioxide ratio is (95%/5%, 2L/min) for continuous perfusion, and pO2 is maintained at 650mmHg during perfusion. During perfusion, continue to use verapamil, amino acid, glucose and insulin. Lactic acid Ringer solution (10ml/h) was used to supplement the lost circulation volume due to urine production during perfusion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic machine perfusion
Description: LifePort Kidney Transporter is designed to integrate with the clinical environment by using readily available supplies, requiring minimal user intervention, and by being easy to use. LifePort Kidney Transporter is a portable, isolated kidney perfusion and transport system, designed to support a donated kidney and to maintain the organ in a near-normal physiologic state under hypothermic aseptic conditions. An insulated plastic housing encloses the kidney and perfusate within a LifePort Kidney Transporter Disposable Perfusion Circuit. LifePort Kidney Transporter components include an Ice Container, Pump Deck, Control Panel, Outer Display, Bubble Detectors, External Connections Panel, sensors, and four lithium-ion batteries. Two handles make the unit easy to lift and carry
Study: NCT04942431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rebirth active SCHOOL 2.0 movement program
Description: 60 Minutes of physical activity per day integrated in every school-day.
Study: NCT05001529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti IL5 receptor antibodies
Description: Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
Study: NCT05726760

Intervention type: DEVICE
Intervention: Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.
Description: The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.

Intervention type: DEVICE
Intervention: Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.
Description: The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.

Intervention type: DEVICE
Intervention: Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.
Description: The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.

Intervention type: DEVICE
Intervention: Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.
Description: The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
Study: NCT03792360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVF (Stromal Vascular Fraction)
Description: The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
Study: NCT05554185

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: aspirin 100mg and probiotics 1 bag
Description: taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: aspirin 100mg and probiotics 1 bag
Description: taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.
Study: NCT06139653

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moment 1: IMT. Moment 2 CardioBreath.
Description: Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.
Study: NCT05228496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg IV D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 1 cycle of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
Study: NCT05860478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable device
Description: The wearable device includes a motion sensor, and is worn around the wrist, and the device records a participant's physical activity .
Study: NCT06139653

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moment 1: CardioBreath and moment 2: IMT.
Description: CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.~Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.
Study: NCT05246514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: administered as an IV infusion
Study: NCT05685784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bytelfies kit - sensor dot
Description: Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.~GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.~PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bytelfies kit - sensor dot
Description: Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.~GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.~PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand
Study: NCT05511402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.